Cinclus Pharma (CINPHA) KOL Event summary

Introduction and agenda

• Event focused on linaprazan glurate, a next-generation PCAB, and its role in addressing unmet needs in GERD, especially severe erosive GERD.

• Agenda included a KOL overview of GERD, limitations of current therapies, real-world patient cases, and a commercial landscape discussion.

KOL background and credentials

• Dr. Prateek Sharma, Professor of Medicine, is internationally recognized for advancing GI disease management and has over 550 publications in top journals.

• He is a frequent speaker at major scientific meetings and has contributed to clinical guidelines and textbooks.

Market insights and analysis

• GERD affects about 20% of the U.S. population and 14% globally, with significant impact on quality of life and work productivity.

• Erosive GERD, especially grades C and D, is associated with higher risks of complications like Barrett's esophagus and esophageal cancer.

• The severe erosive GERD market in the USA and Europe is estimated at 10 million patients, representing a large, dynamic, and chronic market with frequent drug switching.

• PCABs are gaining traction globally, with premium pricing and rapid uptake in markets like Japan and the U.S.